CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced on Monday, that it has named Roger J Pomerantz, MD, FACP as its new chairman effective immediately.
Presently, Dr Pomerantz is the president, chief executive officer and chairman of the board of directors of ContraFect. Dr Pomerantz has extensive board experience and presently serves on the boards of Intec Pharma and VerImmune, in addition to ContraFect. He also serves as the chairman of the Scientific Advisory Board of Aridis Pharmaceuticals. He was also a Venture Partner at Flagship Pioneering from 2014 until 2019. Earlier, he served as the president, chief executive officer and chairman of the board of Seres Therapeutics, where he continues to serve as advisor. Prior to joining Seres, he was senior vice president, worldwide head of Licensing & Acquisition at Merck & Co Inc and prior to that was senior vice president and global franchise head of Infectious Diseases at Merck. Prior to joining Merck, he was global head of Infectious Diseases for Johnson & Johnson Pharmaceuticals.
Yehiel Tal, CollPlant chief executive officer, said, 'Dr Pomerantz's extensive knowledge of the life science industry as a clinician, senior executive and board member is exactly what we need as we bolster our strategic partnerships and clinical development efforts for our recombinant human collagen (rhCollagen) technology platform. Roger is an excellent addition to our team and will play an integral role in our mission to provide optimal treatment options for patients through ground-breaking solutions in the field of regenerative and aesthetic medicine.'
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer